Skip to main content
    I

    Integra LifeSciences Holdings (IART)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $13.53
    +0.36 (+2.69%)

    Market Cap: $1.02B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    87%(34/39)
    Avg Surprise
    +11.20%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.56
    Range$0.55 - $0.59
    9 analysts
    EPS Revisions
    4
    0
    7d
    3
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$0.56+0.9%
    60d ago$0.56+0.2%
    30d ago$0.56+0.2%
    7d ago$0.56+0.2%
    Current$0.56
    Revenue Consensus
    $413M
    Range$410M - $417M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.95
    Range$0.89 - $1.00
    7 analysts
    Revenue Consensus
    $450M
    Range$433M - $462M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.95---
    Sep 26EST
    		-$0.56---
    Jun 26
    Reported Jul 29
    		$0.56$0.48+16.67%Beat+24.4%
    Mar 26
    Reported May 5
    		$0.54$0.40+35.00%Beat+31.7%
    Dec 25
    Reported Feb 26
    		$0.83$0.79+5.06%Beat-14.4%
    Sep 25
    Reported Oct 30
    		$0.54$0.43+25.58%Beat+31.7%
    Jun 25
    Reported Jul 31
    		$0.45$0.43+4.65%Beat-28.6%
    Mar 25
    Reported May 5
    		$0.41$0.43-4.65%Miss-25.5%
    Dec 24
    Reported Feb 25
    		$0.97$0.86+13.40%Beat+9.0%
    Sep 24
    Reported Nov 4
    		$0.41$0.39+5.13%Beat-46.1%
    Jun 24
    Reported Jul 29
    		$0.63$0.62+1.61%Beat-11.3%
    Mar 24
    Reported May 6
    		$0.55$0.55+0.00%Beat-25.7%
    Dec 23
    Reported Feb 28
    		$0.89$0.90-1.11%Miss-5.3%
    Sep 23
    Reported Oct 25
    		$0.76$0.78-2.56%Miss-11.6%
    Jun 23
    Reported Jul 26
    		$0.71$0.57+24.56%Beat-13.4%
    Mar 23
    Reported Apr 26
    		$0.74$0.74+0.00%Beat+0.0%
    Dec 22
    Reported Feb 22
    		$0.94$0.90+4.44%Beat+11.9%
    Sep 22
    Reported Oct 26
    		$0.86$0.72+19.44%Beat+0.0%
    Jun 22
    Reported Jul 27
    		$0.82$0.80+2.50%Beat+3.8%
    Mar 22
    Reported Apr 27
    		$0.74$0.68+8.82%Beat+7.2%
    Dec 21
    Reported Feb 23
    		$0.84$0.83+1.20%Beat+0.0%
    Sep 21
    Reported Nov 2
    		$0.86$0.72+19.44%Beat+7.5%
    Jun 21
    Reported Jul 28
    		$0.79$0.66+19.70%Beat+139.4%
    Mar 21
    Reported Apr 28
    		$0.69$0.57+21.05%Beat+43.7%
    Dec 20
    Reported Feb 18
    		$0.84$0.73+15.07%Beat+23.5%
    Sep 20
    Reported Oct 28
    		$0.80$0.54+48.15%Beat+17.6%
    Jun 20
    Reported Aug 10
    		$0.33$0.15+120.00%Beat-54.8%
    Mar 20
    Reported May 7
    		$0.48$0.63-23.81%Miss-26.2%
    Dec 19
    Reported Feb 19
    		$0.68$0.67+1.49%Beat+4.6%
    Sep 19
    Reported Oct 24
    		$0.68$0.66+3.03%Beat+15.3%
    Jun 19
    Reported Jul 24
    		$0.73$0.66+10.61%Beat+21.7%
    Mar 19
    Reported Apr 24
    		$0.65$0.61+6.56%Beat+12.1%
    Dec 18
    Reported Feb 21
    		$0.65$0.62+4.84%Beat+1.6%
    Sep 18
    Reported Oct 31
    		$0.59$0.59+0.00%Beat+31.1%
    Jun 18
    Reported Jul 25
    		$0.60$0.60+0.00%Beat+33.3%
    Mar 18
    Reported Apr 25
    		$0.58$0.49+18.37%Beat+48.7%
    Dec 17
    Reported Feb 27
    		$0.64$0.56+14.29%Beat+23.1%
    Sep 17
    Reported Oct 26
    		$0.45$0.47-4.26%Miss-
    Jun 17
    Reported Jul 26
    		$0.45$0.45+0.00%Beat-
    Mar 17
    Reported Apr 26
    		$0.39$0.38+2.63%Beat-
    Dec 16
    Reported Feb 23
    		$0.52$0.52+0.00%Beat-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio5.48EV/EBITDA12.36x
    Price/FCF40.53xFCF Yield2.47%
    Profitability
    Profit Margin-0.44%Operating Margin9.62%
    ROE-0.70%ROIC2.40%
    Financial Health
    Debt/Equity1.95xInterest Coverage0.81x
    Current Ratio3.60xQuick Ratio2.11x
    Trading Statistics
    Beta1.21Avg Volume1.16M
    52-Week High$20.4952-Week Low$8.70

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.37
    SMA 20$14.67
    SMA 50$15.91
    SMA 200$14.08
    EMA 10$13.82
    EMA 20$14.42
    EMA 50$15.47
    EMA 200$15.00

    MACD

    Line: -0.78Signal: -0.72Hist: -0.06

    ADX

    ADX: 27.2+DI: 14.9-DI: 31.6

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down68.0
    PSAR$15.48

    Bollinger Bands

    Upper Band$17.44
    Lower Band$11.89
    %B Position3785%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    39.3

    Momentum Oscillators

    Stoch %K26.5
    Stoch %D29.4
    Williams %R-73.3
    ROC (10d)-15.9%
    Momentum-2.56
    CCI (20d)-61.0
    MFI (14d)50.4

    Volatility Measures

    ATR (14d)$0.77(5.7%)
    StdDev (20d)1.39
    Hist Vol87.4%(High)

    Volume Flow

    VWAP$13.48
    OBV14.7M
    AD Line-5.1M
    CMF (20d)0.155

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.0x
    VWMA (20d)$14.26

    Pivot Points

    R3$14.54
    R2$14.16
    R1$13.67
    Pivot Point$13.29
    S1$12.80
    S2$12.43
    S3$11.93

    Advanced Oscillators

    TSI-25.27
    Ultimate Osc47.3
    KST-158.61

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$418.76M$391.92M$434.93M$402.06M$415.61M$382.65M$442.65M$380.83M$418.18M$368.87M$397.04M$382.42M
    Cost of Revenue$199.02M$174.94M$214.06M$195.07M$206.27M$188.22M$193.57M$180.60M$192.26M$162.04M$170.55M$164.08M
    Gross Profit$219.74M$216.98M$220.87M$206.99M$209.33M$194.43M$249.07M$200.24M$225.92M$206.83M$226.49M$218.34M
    Operating Expenses$200.46M$205.51M$197.82M$195.23M$722.01M$209.93M$213.45M$208.39M$228.95M$202.87M$190.45M$191.75M
    R&D$24.25M$23.50M$24.79M$22.46M$27.00M$24.73M$31.21M$27.43M$29.77M$26.96M$24.28M$26.60M
    SG&A$172.44M$178.24M$169.27M$169.05M$179.89M$181.50M$178.52M$177.19M$195.47M$165.80M$163.13M$161.95M
    Operating Income$19.29M$11.47M$23.04M$11.76M$-512,674,000$-15,497,000$35.63M$-8,150,000$-3,029,000$3.96M$36.05M$26.59M
    Interest Income$4.27M$4.11M$4.36M$4.98M$4.71M$4.42M$4.89M$5.05M$5.06M$5.04M$4.55M$4.61M
    Interest Expense$22.99M$22.46M$23.67M$22.73M$21.04M$18.82M$18.98M$19.37M$18.65M$13.62M$13.75M$13.06M
    Income Before Tax$4.74M$-2,409,000$4.31M$-6,824,000$-530,952,000$-30,036,000$22.54M$-20,362,000$-15,185,000$-5,230,000$28.86M$18.61M
    Income Tax Expense$262,000$2.21M$6.01M$-1,420,000$-46,879,000$-4,743,000$3.11M$-9,667,000$-2,783,000$-1,949,000$9.02M$-888,000
    Net Income$4.48M$-4,617,000$-1,704,000$-5,404,000$-484,073,000$-25,293,000$19.43M$-10,695,000$-12,402,000$-3,281,000$19.83M$19.50M
    EBITDA$62.63M$55.38M$63.07M$50.76M$-475,038,000$22.93M$75.62M$31.26M$36.65M$35.32M$70.48M$59.04M
    EBIT$23.47M$15.95M$23.62M$10.92M$-514,620,000$-15,641,000$36.63M$-6,038,000$-1,592,000$3.35M$38.06M$27.06M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IART

    News

    New research on balloon treatment alongside surgery for chronic ear disease will be presented

    Integra LifeSciences will showcase its ENT and instruments portfolios at the 2026 AAO-HNSF Annual Meeting, including the ACCLARENT AERA® Eustachian Tube Treatment. The company is also sponsoring a presentation by Seilesh...

    Stock Titan•10/16/26•Somewhat-Bullish

    Integra Lifesciences Holdings Corp (IART) Shares Surge 4.0% -- What GF Score of 69 Tells Investors

    Integra Lifesciences Holdings Corp (IART) shares surged 4.0% to $13.98, trading significantly below its GF Value™ of $20.48...

    GuruFocus•10/12/26•Somewhat-Bullish

    Integra prices $450M 9.50% senior secured notes due 2033 to refinance debt

    Integra has announced the pricing of $450 million in 9.500% senior secured notes due 2033 through a private placement. The sale is expected to close around October 19, 2026, and the proceeds...

    TradingView•10/9/26•Neutral

    Integra LifeSciences Holdings (IART) Cuts 2026 Revenue Outlook, Is The Stock Below Fair Value?

    Integra LifeSciences Holdings (IART) has cut its 2026 revenue outlook and announced a $600 million debt refinancing plan. Despite recent share price volatility, the stock is considered undervalued by many...

    Yahoo Finance•10/8/26•Somewhat-Bearish

    Before the stock market opens Oct. 21, Integra will release third-quarter results and host a call.

    Integra LifeSciences (NASDAQ: IART) will release its third-quarter 2026 financial results before the market opens on October 21...

    Stock Titan•10/6/26•Neutral

    IART Valuation and Fair Value

    P/E
    5.5x
    Forward P/E
    6.0x
    EV/EBITDA
    12.4x
    P/FCF
    40.5x
    PEG
    0.7x
    P/B
    1.0x
    See GNG's fair value

    IART Profitability: Margins, ROIC and FCF

    Gross margin
    52.5%
    Operating margin
    9.6%
    Net margin
    -0.4%
    ROIC
    2.4%
    ROE
    -0.7%
    FCF margin
    1.6%
    FCF yield
    2.5%

    IART Competitors

    CompanyTicker
    HealthStream IncHSTM
    Opko Health IncOPK
    Artivion IncAORT
    Harrow Health IncHROW
    CureVac NVCVAC
    Castle Biosciences IncCSTL
    Janux Therapeutics IncJANX
    Ventyx Biosciences IncVTYX

    Sector: Healthcare

    IART Analyst Ratings

    Consensus
    Hold
    Analysts
    12
    Strong Buy
    1
    Buy
    2
    Hold
    7
    Sell
    0
    Strong Sell
    2

    IART Bull Case vs Bear Case

    Bull case

    • IART beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • IART has a -0.4% net profit margin.

    IART Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    12.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.56
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 5 down

    IART Dividend

    Forward yield
    0.0%
    Payout ratio
    0.0%

    Frequently Asked Questions About IART

    Does IART pay dividends?

    Integra LifeSciences Holdings (IART) has a dividend payment track record. See the IART dividend history page for its current payment status, TTM yield, and recorded payments.

    What is IART's P/E ratio?

    Integra LifeSciences Holdings has a price-to-earnings (P/E) ratio of 5.48.

    What is IART's market cap?

    Integra LifeSciences Holdings (IART) has a market capitalization of $1.02B with a current stock price of $13.53.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In